Gracell Biotechnologies Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of CNY, except per-share amounts

	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of property, equipment and software
Share-based compensation
Amortization of right-of use assets and interest of lease liabilities
Foreign exchange (gain) loss, net
Changes in operating assets and liabilities:
Prepayments and other current assets
Amounts due to related parties
Accrued liabilities and other current liabilities
Other non-current assets
Lease liabilities
Other non-current liabilities
Net cash used in operating activities
Cash flows from investing activities:
Purchase of property, equipment and software
Investments in short-term investments
Proceeds from disposal of short-term investments
Net cash used in investing activities
Cash flows from financing activities:
Proceeds from initial public offering and over-allotment, net of underwriting commissions
Proceeds from exercise of options and registration of restricted share units
Repayment of convertible loans
Proceeds from issuance of convertible redeemable preferred shares, net of issuance costs
Repurchase of ordinary shares and preferred shares
Proceeds from bank borrowings
Repayments of bank borrowings
Payment of initial public offering costs
Payment of offering costs
Net cash generated from financing activities
Effect of exchange rate on cash and cash equivalents
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at the beginning of year
Cash and cash equivalents at the end of year
Supplemental cashflow disclosures:
Interest paid
Non-cash activities:
Deemed dividend to convertible redeemable preferred shareholders
Accretion of convertible redeemable preferred shares to redemption value
Payables for deferred initial public offering cost

Comments